Skye Bioscience (SKYE) CDO awarded 125,000 stock options at $0.82 strike

Rhea-AI Filing Summary

Skye Bioscience Chief Development Officer granted 125,000 options to buy common stock at an exercise price of $0.82 per share. The award was made on February 6, 2026 and expires on February 6, 2036.

The stock option vests in equal monthly installments over four years beginning January 19, 2026, meaning the officer earns the right to exercise more of the grant every month during that period, as long as service conditions are met.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Diep Tuan Tu

Role Chief Development Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	125,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 125,000 shares (Direct)

Footnotes (1)

1. [object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Diep Tuan Tu

(Last) (First) (Middle)

11250 EL CAMINO REAL

SUITE 100

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Skye Bioscience, Inc. [ SKYE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.82	02/06/2026		A		125,000		(1)	02/06/2036	Common Stock	125,000	$0	125,000	D

Explanation of Responses:

1. The stock option vests in equal monthly installments over the four-year period beginning January 19, 2026.

Remarks:

	/s/ Kaitlyn Arsenault, as Attorney-in-Fact	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Skye Bioscience (SKYE) report in this Form 4?

Skye Bioscience reported a grant of 125,000 stock options to its Chief Development Officer. These options give the right to buy common shares at $0.82 each, with vesting over four years starting January 19, 2026.

Who received stock options in Skye Bioscience (SKYE) and in what role?

Chief Development Officer Diep Tuan Tu received the stock option grant. As a senior executive, this award links compensation to future share performance through 125,000 options that vest monthly over four years and are exercisable at $0.82 per share.

How many Skye Bioscience (SKYE) stock options were granted and at what exercise price?

The filing shows a grant of 125,000 stock options with an exercise price of $0.82 per share. The options are a right to buy common stock and were reported as directly owned following the transaction.

What is the vesting schedule for the Skye Bioscience (SKYE) stock options?

The stock option vests in equal monthly installments over four years beginning January 19, 2026. This means a portion of the 125,000 options becomes exercisable each month, spreading full vesting across the entire four-year period.

When do the Skye Bioscience (SKYE) executive stock options expire?

The options granted to the Chief Development Officer expire on February 6, 2036. After that date, any unexercised portion of the 125,000 stock options at the $0.82 exercise price will no longer be usable by the executive.

Is the Skye Bioscience (SKYE) Form 4 transaction a purchase or a grant?

The Form 4 reports an acquisition coded as an option grant, not an open-market share purchase. The executive received 125,000 stock options at a $0.82 exercise price, with no cash price listed for acquiring the option itself.